NASDAQ:MEDP Medpace (MEDP) Stock Forecast, Price & News $207.08 +3.53 (+1.73%) (As of 01:51 PM ET) Add Compare Share Share Today's Range$204.16▼$208.5750-Day Range$178.78▼$210.8852-Week Range$130.79▼$241.48Volume125,107 shsAverage Volume331,131 shsMarket Capitalization$6.32 billionP/E Ratio26.21Dividend YieldN/APrice Target$241.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Medpace MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside16.5% Upside$241.00 Price TargetShort InterestBearish8.70% of Float Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment1.49Based on 5 Articles This WeekInsider TradingSelling Shares$7.02 M Sold Last QuarterProj. Earnings Growth13.32%From $8.11 to $9.19 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.38 out of 5 starsMedical Sector241st out of 1,009 stocksCommercial Physical Research Industry8th out of 16 stocks 2.2 Analyst's Opinion Consensus RatingMedpace has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $241.00, Medpace has a forecasted upside of 16.5% from its current price of $206.87.Amount of Analyst CoverageMedpace has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.70% of the float of Medpace has been sold short.Short Interest Ratio / Days to CoverMedpace has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Medpace has recently increased by 3.59%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMedpace does not currently pay a dividend.Dividend GrowthMedpace does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedpace has received a 72.85% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Medical devices engineering", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Medpace is -0.62. Previous Next 2.5 News and Social Media Coverage News SentimentMedpace has a news sentiment score of 1.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Medpace this week, compared to 6 articles on an average week.Search InterestOnly 10 people have searched for MEDP on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medpace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,020,476.00 in company stock.Percentage Held by Insiders25.70% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.49% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Medpace are expected to grow by 13.32% in the coming year, from $8.11 to $9.19 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medpace is 26.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.10.Price to Earnings Ratio vs. SectorThe P/E ratio of Medpace is 26.19, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 90.44.Price to Book Value per Share RatioMedpace has a P/B Ratio of 16.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Medpace (NASDAQ:MEDP) StockMedpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.Read More Receive MEDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter. Email Address MEDP Stock News HeadlinesMay 18, 2023 | finance.yahoo.comHere's Why We Think Medpace Holdings (NASDAQ:MEDP) Might Deserve Your Attention TodayMay 14, 2023 | americanbankingnews.comMedpace (NASDAQ:MEDP) Upgraded to Buy by StockNews.comMay 30, 2023 | Edge On The Street (Ad)Is Graphite the New Lithium?Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.May 12, 2023 | americanbankingnews.com22nd Century Group Reaffirms "Upgrade" Rating for Medpace (NASDAQ:MEDP)May 10, 2023 | msn.comGuggenheim Upgrades Medpace Holdings (MEDP)May 10, 2023 | msn.comMedpace: Gaining Market Share While Others StruggleMay 8, 2023 | americanbankingnews.comMedpace (NASDAQ:MEDP) Rating Increased to Buy at GuggenheimMay 8, 2023 | americanbankingnews.comFinancial Contrast: Medpace (NASDAQ:MEDP) and bioAffinity Technologies (NASDAQ:BIAF)May 30, 2023 | Edge On The Street (Ad)Is Graphite the New Lithium?Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.May 6, 2023 | finance.yahoo.comMedpace Holdings Crushed Analyst ExpectationsMay 6, 2023 | americanbankingnews.comMedpace (NASDAQ:MEDP) Stock Rating Lowered by StockNews.comMay 4, 2023 | finance.yahoo.comIs There An Opportunity With Medpace Holdings, Inc.'s (NASDAQ:MEDP) 21% Undervaluation?May 4, 2023 | americanbankingnews.comMedpace Holdings, Inc. (NASDAQ:MEDP) Sees Significant Growth in Short InterestMay 2, 2023 | finance.yahoo.comMedpace Holdings, Inc. (NASDAQ:MEDP) Q1 2023 Earnings Call TranscriptApril 29, 2023 | americanbankingnews.comMedpace (NASDAQ:MEDP) Stock Price Down 6.3% on Insider SellingApril 29, 2023 | americanbankingnews.comMedpace (NASDAQ:MEDP) Rating Increased to Buy at StockNews.comApril 29, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Medpace Holdings, Inc. Increased by Analyst (NASDAQ:MEDP)April 28, 2023 | americanbankingnews.comMedpace Holdings, Inc. (NASDAQ:MEDP) Expected to Earn Q3 2023 Earnings of $1.95 Per ShareApril 28, 2023 | americanbankingnews.comMedpace Holdings, Inc. (NASDAQ:MEDP) CEO August J. Troendle Sells 31,648 SharesApril 27, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Medpace Holdings, Inc. (NASDAQ:MEDP) Lifted by William BlairApril 26, 2023 | finance.yahoo.comQ1 2023 Medpace Holdings Inc Earnings CallApril 25, 2023 | seekingalpha.comMedpace Holdings, Inc. 2023 Q1 - Results - Earnings Call PresentationApril 24, 2023 | finance.yahoo.comMedpace Holdings, Inc. Reports First Quarter 2023 ResultsApril 24, 2023 | finance.yahoo.comMedpace, A Top 1% Earnings Stock, Just Crushed Expectations — Here's A Key Measure To WatchApril 24, 2023 | seekingalpha.comMedpace Q1 2023 Earnings PreviewApril 24, 2023 | markets.businessinsider.comHere's what Wall Street expects from Medpace's earningsApril 22, 2023 | americanbankingnews.comMedpace (MEDP) Scheduled to Post Quarterly Earnings on MondaySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MEDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter. Email Address MEDP Company Calendar Last Earnings4/24/2023Today5/30/2023Next Earnings (Estimated)7/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MEDP CUSIPN/A CIK1668397 Webwww.medpace.com Phone(513) 579-9911Fax513-579-0444Employees5,200Year FoundedN/APrice Target and Rating Average Stock Price Forecast$241.00 High Stock Price Forecast$252.00 Low Stock Price Forecast$233.00 Forecasted Upside/Downside+18.4%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$7.90 Trailing P/E Ratio25.77 Forward P/E Ratio25.10 P/E GrowthN/ANet Income$245.37 million Net Margins16.44% Pretax Margin19.42% Return on Equity75.20% Return on Assets19.06% Debt Debt-to-Equity RatioN/A Current Ratio0.42 Quick Ratio0.42 Sales & Book Value Annual Sales$1.56 billion Price / Sales3.97 Cash Flow$8.59 per share Price / Cash Flow23.70 Book Value$12.42 per share Price / Book16.39Miscellaneous Outstanding Shares30,499,000Free Float22,661,000Market Cap$6.21 billion OptionableOptionable Beta1.42 Key ExecutivesAugust James TroendleChairman & Chief Executive OfficerJesse J. GeigerPresidentSusan E. BurwigExecutive Vice President-OperationsKevin M. BradyChief Financial Officer & TreasurerBrandon EbkenChief Information OfficerKey CompetitorsSyneos HealthNASDAQ:SYNHCharles River Laboratories InternationalNYSE:CRLIncyteNASDAQ:INCYICON PublicNASDAQ:ICLRExelixisNASDAQ:EXELView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,041 shares on 5/26/2023Ownership: 0.022%Capital Impact Advisors LLCBought 2,341 shares on 5/23/2023Ownership: 0.008%Ameriprise Financial Inc.Bought 2,939 shares on 5/22/2023Ownership: 0.560%Putnam Investments LLCBought 290 shares on 5/22/2023Ownership: 0.305%Centaurus Financial Inc.Bought 125 shares on 5/18/2023Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions MEDP Stock - Frequently Asked Questions Should I buy or sell Medpace stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MEDP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEDP, but not buy additional shares or sell existing shares. View MEDP analyst ratings or view top-rated stocks. What is Medpace's stock price forecast for 2023? 3 analysts have issued 12 month price targets for Medpace's shares. Their MEDP share price forecasts range from $233.00 to $252.00. On average, they expect the company's stock price to reach $241.00 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price. View analysts price targets for MEDP or view top-rated stocks among Wall Street analysts. How have MEDP shares performed in 2023? Medpace's stock was trading at $212.41 at the beginning of 2023. Since then, MEDP stock has decreased by 4.2% and is now trading at $203.55. View the best growth stocks for 2023 here. When is Medpace's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 24th 2023. View our MEDP earnings forecast. How were Medpace's earnings last quarter? Medpace Holdings, Inc. (NASDAQ:MEDP) released its earnings results on Monday, April, 24th. The company reported $2.27 EPS for the quarter, beating analysts' consensus estimates of $1.76 by $0.51. The business earned $434.07 million during the quarter, compared to the consensus estimate of $402.83 million. Medpace had a trailing twelve-month return on equity of 75.20% and a net margin of 16.44%. The firm's revenue was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.69 EPS. What ETFs hold Medpace's stock? ETFs with the largest weight of Medpace (NASDAQ:MEDP) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Argent Mid Cap ETF (AMID), AdvisorShares Dorsey Wright Alpha Equal Weight ETF (DWEQ), Global X Founder-Run Companies ETF (BOSS), Invesco S&P MidCap Quality ETF (XMHQ), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and Pacer Lunt MidCap Multi-Factor Alternator ETF (PAMC). What guidance has Medpace issued on next quarter's earnings? Medpace issued an update on its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $7.81-$8.40 for the period, compared to the consensus earnings per share estimate of $7.76. The company issued revenue guidance of $1.75 billion-$1.80 billion, compared to the consensus revenue estimate of $1.71 billion. What is August Troendle's approval rating as Medpace's CEO? 268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Medpace own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG). When did Medpace IPO? (MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers. What is Medpace's stock symbol? Medpace trades on the NASDAQ under the ticker symbol "MEDP." Who are Medpace's major shareholders? Medpace's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.43%), Wasatch Advisors LP (6.09%), State Street Corp (2.76%), Geode Capital Management LLC (1.93%), Boston Trust Walden Corp (1.83%) and Dimensional Fund Advisors LP (1.77%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc. View institutional ownership trends. How do I buy shares of Medpace? Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Medpace's stock price today? One share of MEDP stock can currently be purchased for approximately $203.55. How much money does Medpace make? Medpace (NASDAQ:MEDP) has a market capitalization of $6.21 billion and generates $1.56 billion in revenue each year. The company earns $245.37 million in net income (profit) each year or $7.90 on an earnings per share basis. How many employees does Medpace have? The company employs 5,200 workers across the globe. How can I contact Medpace? Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The official website for the company is www.medpace.com. The company can be reached via phone at (513) 579-9911, via email at investor@medpace.com, or via fax at 513-579-0444. This page (NASDAQ:MEDP) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medpace Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.